로봇 생검 기기 시장 : 제품 유형, 기술, 시술 유형, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Robotic Biopsy Devices Market is projected to grow by USD 1,106.61 million at a CAGR of 11.66% by 2032.

Robotic Biopsy Devices Market Introduction

Robotic biopsy devices are moving from niche navigation tools to core infrastructure for minimally invasive cancer diagnosis. The category spans robotic bronchoscopy platforms for peripheral lung lesions, image-guided needle-placement systems for prostate, breast, liver, kidney, and musculoskeletal biopsies, and integrated workflows that combine robotics with CT, MRI, ultrasound, cone-beam CT, fluoroscopy, and digital pathology.

Demand is anchored in a measurable clinical need: the International Agency for Research on Cancer reported an estimated 20 million new cancer cases worldwide in 2022, with lung cancer the most commonly diagnosed cancer globally. As screening programs detect smaller and harder-to-reach lesions, hospitals are prioritizing robotic biopsy technologies that improve access, stabilize instruments, standardize sampling, and reduce repeat procedures. For manufacturers, the competitive field is defined by precision, workflow integration, clinical evidence, reimbursement fit, and regulatory trust.

Transformative Shifts in the Robotic Biopsy Landscape

The robotic biopsy devices landscape is being reshaped by the convergence of robotics, advanced imaging, and minimally invasive intervention. Robotic bronchoscopy is gaining relevance as low-dose CT lung screening identifies peripheral nodules that are difficult to access with conventional bronchoscopy, while MRI-ultrasound fusion and robotic needle guidance are supporting more targeted tissue acquisition in urology and interventional radiology.

Procurement decisions are also shifting from device-only evaluation to system-level value. Health systems increasingly assess robotic biopsy devices based on diagnostic yield, procedure time, anesthesia requirements, compatibility with existing imaging suites, training burden, service uptime, infection-control requirements, and data connectivity. Vendors that can document clinical performance across lesion size, location, and patient risk profiles are better positioned as hospitals move toward evidence-based capital purchasing.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of robotic biopsy devices by strengthening the full diagnostic pathway. AI-enabled imaging tools can assist with lesion detection, segmentation, risk stratification, trajectory planning, and respiratory motion analysis, while robotics can translate those insights into more stable instrument navigation and repeatable needle placement.

The impact is cumulative rather than isolated. AI can support pre-procedure planning, intra-procedure navigation, post-procedure quality checks, and pathology triage, helping reduce variability across operators and sites. Regulatory scrutiny remains essential, particularly around data quality, algorithm validation, cybersecurity, transparency, and human oversight; however, the FDA's expanding public catalog of AI/ML-enabled medical devices indicates that clinical adoption of regulated AI is no longer experimental but increasingly operational.

Key Regional Insights for Robotic Biopsy Devices

North America remains a highly influential region for robotic biopsy device adoption, supported by high imaging capacity, established cancer screening guidance, academic medical centers, and reimbursement pathways for image-guided procedures. The United States is particularly important because of FDA-cleared navigation technologies, lung cancer screening recommendations from national preventive health authorities, and a strong base of interventional pulmonology, urology, and radiology programs. Canada follows a more centralized procurement model, where hospital networks emphasize clinical evidence, cost-effectiveness, service coverage, and equitable access across provinces.

Europe is shaped by strict regulatory oversight under the EU Medical Device Regulation, broad cancer-control initiatives, and strong adoption capacity in Germany, France, Italy, Spain, and the United Kingdom. Asia-Pacific is a fast-evolving opportunity as China, Japan, South Korea, India, and Australia expand cancer diagnostics, tertiary care capacity, minimally invasive surgery, and medical robotics investment. Latin America, led by Brazil and Mexico, is advancing through private hospital systems, oncology centers, and demand for image-guided interventions, while the Middle East is prioritizing high-end hospital modernization in GCC markets. Africa remains earlier in adoption, with opportunities tied to diagnostic infrastructure, specialist training, imaging availability, and public-private investment.

Key Group Insights Across Major Economic and Strategic Blocs

Within the European Union, harmonized regulatory expectations, cross-border clinical research, health technology assessment processes, and cancer screening initiatives create a structured environment for robotic biopsy device evaluation. The G7 markets remain central to premium adoption because they combine advanced imaging fleets, specialist physician networks, high healthcare expenditure, and established pathways for complex interventional procedures. NATO countries benefit from technology standardization, supply-chain resilience priorities, and investment in medical readiness, which can support adoption of reliable, interoperable, and serviceable medical technologies.

BRICS countries represent scale-driven demand, especially as China, India, and Brazil expand oncology infrastructure, imaging access, and domestic medical device capabilities. ASEAN markets are heterogeneous but attractive, with Singapore, Thailand, Malaysia, Vietnam, Indonesia, and the Philippines investing in specialty care, cancer diagnostics, and hospital modernization at different speeds. The GCC is a high-value cluster for robotic biopsy suppliers due to hospital modernization, medical tourism strategies, government-backed digital health programs, and demand for advanced minimally invasive oncology diagnostics.

Key Country Insights for Robotic Biopsy Device Adoption

The United States leads commercialization because it combines clinical innovation, FDA pathways, lung screening programs, and high procedural volumes across interventional pulmonology, radiology, and urology. Canada emphasizes clinical evidence, centralized adoption, and equitable access. Mexico and Brazil are important Latin American demand centers, supported by private hospitals, expanding oncology services, and investment in advanced imaging. In Europe, the United Kingdom, Germany, France, Italy, and Spain prioritize cancer diagnostics and minimally invasive care, while Russia's environment is shaped by localized procurement, technology access constraints, and healthcare modernization priorities.

China is scaling domestic robotics, hospital infrastructure, and imaging capacity; India offers long-term procedural potential as oncology access and tertiary care expand; Japan contributes advanced robotics expertise and mature hospital systems; South Korea is strong in digital hospitals, imaging, and precision medicine; and Australia benefits from mature screening systems, specialist referral networks, and high standards for evidence-based adoption. Across these countries, adoption depends on the same fundamentals: verified diagnostic yield, safe navigation to difficult lesions, physician training, reimbursement clarity, regulatory compliance, service reliability, and integration with existing imaging infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinical evidence that demonstrates diagnostic yield, complication rates, procedure efficiency, sample adequacy, and performance in small, peripheral, or anatomically difficult lesions. Claims should be supported by peer-reviewed studies, registry data, and post-market surveillance rather than promotional benchmarks. Vendors should also design robotic biopsy platforms that integrate smoothly with CT, MRI, ultrasound, cone-beam CT, PACS, navigation software, electronic health records, and pathology workflows.

Commercial teams should align value propositions with each buyer's reality: high-throughput cancer centers need productivity and precision, regional hospitals need training simplicity and reliability, and emerging markets need scalable service models and durable technical support. Leaders should invest in AI governance, cybersecurity, remote support, physician education, regulatory readiness, and outcome-based partnerships with hospitals to build durable trust in robotic biopsy devices.

Research Methodology

This executive summary is developed through secondary research and market intelligence synthesis using publicly available, verifiable sources. Inputs include cancer burden data from the International Agency for Research on Cancer and World Health Organization, regulatory references from the U.S. FDA and European authorities, screening guidance from recognized public health bodies, and clinical literature on image-guided biopsy, robotic bronchoscopy, targeted needle placement, and minimally invasive oncology diagnostics.

The analysis triangulates clinical adoption drivers, regulatory dynamics, regional healthcare infrastructure, reimbursement considerations, technology trends, and procurement factors. Emphasis is placed on evidence-based interpretation rather than unverified market sizing, ensuring that the discussion remains relevant for executives, investors, manufacturers, distributors, hospitals, clinicians, and procurement stakeholders in robotic biopsy devices.

Conclusion

Robotic biopsy devices are becoming a strategic enabler of earlier, more precise, and less invasive cancer diagnosis. The strongest opportunities are emerging where screening programs, imaging capacity, specialty training, regulatory readiness, and reimbursement systems align with the clinical need to sample smaller and more complex lesions.

Artificial intelligence, advanced imaging, and robotic navigation will continue to reinforce each other, but adoption will depend on proven outcomes, workflow value, regulatory compliance, service reliability, and total cost of ownership. Companies that combine clinical credibility with scalable implementation will be best positioned to lead the next phase of the robotic biopsy devices market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Robotic Biopsy Devices Market, by Product Type

• 7.1. Robotic Systems
• 7.2. Instruments & Accessories
  • 7.2.1. Biopsy Needles
  • 7.2.2. Robotic Probes
  • 7.2.3. Biopsy Forceps
  • 7.2.4. Disposable Kits
  • 7.2.5. Guidance Sheaths

8. Robotic Biopsy Devices Market, by Technology

• 8.1. Imaging Guidance Technology
  • 8.1.1. CT-guided Robotic Biopsy
  • 8.1.2. MRI-guided Robotic Biopsy
  • 8.1.3. Ultrasound-guided Robotic Biopsy
• 8.2. Navigation Technology
  • 8.2.1. Electromagnetic Navigation
  • 8.2.2. Optical Navigation
  • 8.2.3. GPS-based Tracking

9. Robotic Biopsy Devices Market, by Procedure Type

• 9.1. Percutaneous Biopsy
• 9.2. Endoscopic Biopsy
• 9.3. Stereotactic Biopsy
• 9.4. Laparoscopic Biopsy
• 9.5. Transbronchial Biopsy

10. Robotic Biopsy Devices Market, by Application

• 10.1. Breast Biopsy
• 10.2. Kidney Biopsy
• 10.3. Liver Biopsy
• 10.4. Lung Biopsy
• 10.5. Prostate Biopsy

11. Robotic Biopsy Devices Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Diagnostic Centers
• 11.3. Hospitals
  • 11.3.1. Public Hospitals
  • 11.3.2. Private Hospitals
• 11.4. Academic & Research Institutes

12. Robotic Biopsy Devices Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Robotic Biopsy Devices Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Robotic Biopsy Devices Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Asensus Surgical, Inc.
• 16.2. Biobot Surgical Pte Ltd
• 16.3. Brainlab AG
• 16.4. CMR Surgical Ltd
• 16.5. EndoQuest Robotics Inc.
• 16.6. Intuitive Surgical, Inc.
• 16.7. iSYS Medizintechnik GmbH
• 16.8. Medicaroid Corporation
• 16.9. Medrobotics Corporation
• 16.10. Medtronic plc
• 16.11. Mendaera, Inc.
• 16.12. Microsure B.V.
• 16.13. Monteris Medical
• 16.14. Neocis, Inc.
• 16.15. Noah Medical
• 16.16. PROCEPT BioRobotics Corp.
• 16.17. Renishaw plc
• 16.18. Revo Surgical
• 16.19. Smith & Nephew plc
• 16.20. Stryker Corporation
• 16.21. Think Surgical, Inc.
• 16.22. Virtual Incision Corporation
• 16.23. XACT Robotics Ltd.
• 16.24. Zimmer Biomet Holdings, Inc.